Ofev under the microscope: Real-World safety data for lung disease patients
NCT ID NCT04559581
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study monitored 425 Japanese patients with chronic fibrosing interstitial lung diseases that are getting worse over time (PF-ILD) who were prescribed Ofev capsules. Researchers tracked side effects, especially liver problems, to see how safe the drug is in everyday use. The goal was to gather real-world safety information, not to test if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nintedanib (Ofev)
- What this could lead to
- If successful, this study could confirm that Ofev is safe and tolerable for Japanese patients with PF-ILD, supporting its continued use to slow lung damage.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove effectiveness. Side effects like liver problems may still occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASES, INTERSTITIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can scans replace breathing tests to monitor lung scarring?
- Skin patch could replace needle sticks during exercise tests
- Pigeon Lovers' lung disease: genes may hold the key
- New study tracks lung disease in rheumatic patients
- Lung biopsy without a breathing tube? small study tests a gentler approach
- New injection aims to ease lung pressure in scarred lungs